.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Predict branded drug patent expiration

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
Medtronic
Colorcon
Chinese Patent Office
Daiichi Sankyo
Covington
Cerilliant
Harvard Business School
McKesson
QuintilesIMS

Generated: July 23, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Which drugs does patent 5,968,976 protect, and when does it expire?


Patent ► Subscribe protects FOSRENOL and is included in two NDAs. There have been two Paragraph IV challenges on Fosrenol.

This patent has thirty-five patent family members in twenty-seven countries.

Summary for Patent: ► Subscribe

Title: Pharmaceutical composition containing selected lanthanum carbonate hydrates
Abstract:Selected lanthanum carbonate hydrates may be administered into the gastrointestinal tract, to treat hyperphosphataemia in patients with renal failure.
Inventor(s): Murrer; Barry A (Berkshire, GB), Powell; Nigel A (Berkshire, GB)
Assignee: AnorMed Inc. (Langley, CA)
Application Number:08/913,960
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form; Process; Formulation;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Shire Dev Llc
FOSRENOL
lanthanum carbonate
POWDER;ORAL204734-002Sep 24, 2014RXYesYes► Subscribe► SubscribeY TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
Shire Dev Llc
FOSRENOL
lanthanum carbonate
POWDER;ORAL204734-001Sep 24, 2014RXYesNo► Subscribe► SubscribeY TO REDUCE SERUM PHOSPHATE IN PATIENTS WITH END STAGE RENAL DISEASE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-004Nov 23, 2005RXYesYes► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-001Oct 26, 2004DISCNNoNo► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
Shire Llc
FOSRENOL
lanthanum carbonate
TABLET, CHEWABLE;ORAL021468-002Oct 26, 2004RXYesNo► Subscribe► SubscribeY REDUCTION OF SERUM PHOSPHATE
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: ► Subscribe

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom9506126Mar 25, 1995
PCT Information
PCT FiledMarch 19, 1996PCT Application Number:PCT/GB96/00575
PCT Publication Date:October 03, 1996PCT Publication Number: WO96/30029

International Patent Family for Patent: ► Subscribe

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office0817639► SubscribeSPC/GB06/036United Kingdom► Subscribe
European Patent Office0817639► SubscribePA2008005Lithuania► Subscribe
European Patent Office0817639► SubscribePA2008005,C0817639Lithuania► Subscribe
Estonia04096► Subscribe
Estonia9700325► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Citi
Deloitte
Boehringer Ingelheim
US Army
Medtronic
Moodys
Teva
Cerilliant
Merck
Julphar

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot